Pediatrics. 2022 Oct 1;150(4). doi: 10.1542/peds.2022-059275.
This technical report accompanies the recommendations of the American Academy of Pediatrics for the routine use of influenza vaccine and antiviral medications in the prevention and treatment of influenza in children during the 2022 to 2023 season. The American Academy of Pediatrics recommends annual influenza vaccination of all children without medical contraindications starting at 6 months of age. Influenza vaccination is an important strategy for protecting children and the broader community as well as reducing the overall burden of respiratory illnesses when other viruses, including severe acute respiratory syndrome-coronavirus 2, are cocirculating. This technical report summarizes recent influenza seasons, morbidity and mortality in children, vaccine effectiveness, and vaccination coverage, and provides detailed guidance on storage, administration, and implementation. The report also provides a brief background on inactivated and live attenuated influenza vaccine recommendations, vaccination during pregnancy and breastfeeding, diagnostic testing, and antiviral medications for treatment and chemoprophylaxis. Updated information is provided about the 2021 to 2022 influenza season, influenza immunization rates, the effectiveness of influenza vaccination on hospitalization and mortality, available vaccines, guidance for patients with history of severe allergic reactions to prior influenza vaccinations, and strategies to promote vaccine uptake.
本技术报告伴随美国儿科学会针对 2022-2023 季在儿童中预防和治疗流感的常规使用流感疫苗和抗病毒药物的建议。美国儿科学会建议自 6 个月龄起所有无医学禁忌证的儿童常规接种流感疫苗。流感疫苗接种是保护儿童和更广泛社区的重要策略,当其他病毒(包括严重急性呼吸综合征冠状病毒 2 型)共同传播时,还可以减轻呼吸道疾病的总体负担。本技术报告总结了最近的流感季节、儿童发病率和死亡率、疫苗有效性和疫苗接种覆盖率,并就储存、管理和实施提供了详细指导。该报告还简要介绍了灭活和减毒流感疫苗推荐、妊娠和哺乳期接种、诊断检测以及治疗和化学预防用抗病毒药物。提供了关于 2021-2022 流感季节、流感免疫接种率、流感疫苗接种对住院和死亡率的有效性、可用疫苗、对既往流感疫苗接种有严重过敏反应史患者的指导以及提高疫苗接种率的策略的最新信息。